🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Galectin Therapeutics Inc. (GALT)
NASDAQ: GALT · Real-Time Price · USD
2.980
+0.070 (2.41%)
Nov 18, 2026, 4:00 PM EST - Market closed

Galectin Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
-23.19-30.84-47.05-41.07-38.78-30.53
Depreciation & Amortization
0.090.050.040.030.030.04
Stock-Based Compensation
2.791.662.452.262.872.08
Other Operating Activities
2.354.640.511.13-0.150.15
Change in Accounts Payable
-2.73-6.04-2.072.674.243.69
Change in Other Net Operating Assets
6.086.654.362.010.720.27
Operating Cash Flow
-14.61-23.88-41.77-32.97-31.06-24.31
Operating Cash Flow Growth
------

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-2130301030
Net Debt Issued (Repaid)
102130301030
Issuance of Common Stock
4.795.481.2310.03-6.81
Financing Cash Flow
14.7926.4831.2340.031036.81

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
0.182.6-10.547.07-21.0612.51

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Levered Free Cash Flow
-13.27-20.9-29.31-20.68-17.56-13.23
Unlevered Free Cash Flow
-9.07-16.32-25.84-18.93-16.91-12.92

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
3.350.612.284.684.973.96
SEC Filings: 10-K · 10-Q